Drug intelligence / Profile preview

lyophilized human rabies vaccine (Vero cell)

Development stage
Unknown
Lead developer
Ningbo Rongan Biological Pharmaceutical
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The lyophilized human rabies vaccine (Vero cell), also known as the freeze-dried human rabies vaccine (Vero cell), is an approved inactivated vaccine developed by AIM Kanghuai Biopharmaceutical, a subsidiary of AIM Vaccine. Produced using Vero cells, the vaccine is formulated in a lyophilized (freeze-dried) form to improve stability during storage and transportation compared to earlier liquid formulations. Its active ingredient consists of inactivated rabies virus antigens, which work by inducing protective immunity against rabies virus antigens in the recipient. The vaccine is indicated for the prevention of rabies and has been evaluated under both the Essen (5-dose) and Zagreb (4-dose, 2-1-1) vaccination regimens in clinical trials involving healthy participants aged 10–60 years in China.

Other names
freeze-dried human rabies vaccine (Vero cell)freeze-dried rabies vaccine for human use (Vero cell)lyophilized rabies vaccine for human use (Vero cell)
02

Targets

RABV-G (Rabies virus glycoprotein)Rabies virus nucleoprotein

Beyond the preview

Go deeper on lyophilized human rabies vaccine (Vero cell).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lyophilized human rabies vaccine (Vero cell).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call